HENRY SCHEIN INC HSIC
technology.
based dental and medical practitioners, as well as alternate sites of care.
practitioner can provide better clinical care.
With 94 years of experience distributing health care products, we have built a vast base of small, mid-sized
Last close
89.81
2026-09-04
Market cap
$10.01B
2026-06-27 share count
52-week range
61.95 - 92.18
Valuation FY2025 figures against the last close
P/S0.8x
P/E27.5x
P/FCF17.5x
EV/EBITDA11.0x
Dividend yield—
Diluted EPS3.27
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.18B | $12.67B | $12.34B | $12.65B | $12.40B | $10.12B | $9.99B | $9.42B | $8.88B | $11.57B |
| Cost of revenue | $9.08B | $8.66B | $8.48B | $8.82B | $8.73B | $7.30B | $6.89B | $6.51B | $6.14B | $8.35B |
| Gross profit | $4.11B | $4.02B | $3.86B | $3.83B | $3.67B | $2.82B | $3.09B | $2.91B | $2.75B | $3.23B |
| SG&A | $3.08B | $3.03B | $2.96B | $2.77B | $2.63B | $2.09B | $2.36B | $2.22B | $2.07B | $2.41B |
| Total operating expenses | — | — | — | — | — | — | — | $2.70B | $2.53B | $2.41B |
| Operating income | $653.0M | $621.0M | $615.0M | $747.0M | $852.0M | $535.0M | $718.3M | $600.6M | $669.8M | $771.6M |
| Interest expense | $150.0M | $131.0M | $87.0M | $35.0M | $27.0M | $41.0M | $50.8M | $76.0M | $51.1M | $31.9M |
| Pre-tax income | $533.0M | $513.0M | $542.0M | $721.0M | $831.0M | $500.0M | $680.3M | $536.8M | $629.8M | $755.8M |
| Income tax | $126.0M | $128.0M | $120.0M | $170.0M | $198.0M | $95.0M | $159.5M | $107.4M | $309.0M | $218.0M |
| Net income | $419.0M | $398.0M | $436.0M | $566.0M | $660.0M | $404.0M | $694.7M | $535.9M | $406.3M | $506.8M |
| EPS, basic | 3.29 | 3.07 | 3.18 | 3.95 | 4.51 | 2.83 | 4.70 | 3.51 | 2.59 | 3.14 |
| EPS, diluted | 3.27 | 3.05 | 3.16 | 3.91 | 4.45 | 2.82 | 4.65 | 3.49 | 2.57 | 3.10 |
| Shares, diluted (wtd. avg.) | $121.7M | $127.8M | $131.7M | $137.8M | $141.8M | $143.4M | $149.3M | $153.7M | $158.2M | $163.7M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $156.0M | $122.0M | $171.0M | $117.0M | $118.0M | $421.0M | $106.1M | $56.9M | $158.0M | $42.7M |
| Receivables | $1.65B | $1.48B | $1.86B | $1.44B | $1.45B | $1.42B | $1.25B | $1.17B | $1.52B | $1.25B |
| Inventory | $2.00B | $1.81B | $1.81B | $1.96B | $1.86B | $1.51B | $1.43B | $1.42B | $1.93B | $1.67B |
| Total current assets | $4.46B | $3.98B | $4.49B | $3.99B | $3.84B | $3.79B | $3.23B | $4.18B | $4.09B | $3.34B |
| Property, plant and equipment | — | — | — | — | $366.5M | $342.0M | $329.6M | $314.2M | $375.0M | $333.9M |
| Goodwill | $4.21B | $3.89B | $3.88B | $2.89B | $2.85B | $2.50B | $2.46B | $2.08B | $1.55B | $2.02B |
| Other intangibles | $1.02B | $1.02B | $916.0M | $587.0M | $668.0M | $479.4M | $572.9M | $376.0M | $669.6M | $621.2M |
| Total assets | $11.21B | $10.22B | $10.57B | $8.61B | $8.48B | $7.77B | $7.15B | $8.50B | $7.86B | $6.81B |
| Accounts payable | $1.15B | $962.0M | $1.02B | $1.00B | $1.05B | $1.01B | $880.3M | $785.8M | $1.15B | $1.01B |
| Short-term debt | $764.0M | $650.0M | $264.0M | $103.0M | $51.0M | $73.4M | $24.0M | $951.5M | — | — |
| Total current liabilities | $3.23B | $2.80B | $2.68B | $2.22B | $2.31B | $2.28B | $2.04B | $3.22B | $2.83B | $2.32B |
| Long-term debt | — | — | — | $1.05B | $822.0M | — | — | — | — | — |
| Total liabilities | $6.42B | $5.38B | $5.42B | $3.94B | $3.81B | $3.46B | $3.23B | $4.65B | $4.21B | $3.35B |
| Retained earnings | $3.29B | $3.77B | $3.86B | $3.68B | $3.60B | $3.45B | $3.12B | $3.21B | $2.94B | $2.98B |
| Total equity | $3.25B | $3.39B | $4.29B | $4.09B | $4.06B | $3.98B | $3.63B | $3.54B | $2.82B | $2.80B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $712.0M | $848.0M | $500.0M | $602.0M | $710.0M | $599.0M | $654.1M | $684.7M | $545.5M | $642.6M |
| Depreciation and amortisation | $311.0M | $297.0M | $248.0M | $212.0M | $210.0M | $186.0M | $184.9M | $143.6M | $133.9M | $169.8M |
| Stock-based compensation | $39.0M | $39.0M | $39.0M | $54.0M | $78.0M | $9.0M | $44.9M | $32.6M | $36.8M | $58.2M |
| Capital expenditure | $139.0M | $148.0M | $147.0M | $96.0M | $79.0M | $49.0M | $76.2M | $71.3M | $62.4M | $70.2M |
| Investing cash flow | -$400.0M | -$430.0M | -$1.14B | -$276.0M | -$677.0M | -$115.0M | -$424.4M | -$193.0M | -$342.3M | -$316.4M |
| Financing cash flow | -$188.0M | -$510.0M | $701.0M | -$315.0M | -$333.0M | -$187.0M | -$216.0M | -$603.8M | -$112.6M | -$327.3M |
| Buybacks | $850.0M | $385.0M | $250.0M | $485.0M | $401.0M | $74.0M | $525.0M | $200.0M | $450.0M | $550.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-146317.
Others in SIC 5047
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ACH | ACCENDRA HEALTH INC/VA/ | $93.1M | — | 3.1% |